Pacira Pharmaceuticals Inc (NASDAQ:PCRX) Director Andreas Wicki sold 58,245 shares of the firm’s stock in a transaction dated Friday, November 9th. The shares were sold at an average price of $51.11, for a total value of $2,976,901.95. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of Pacira Pharmaceuticals stock traded down $0.47 during trading on Tuesday, reaching $47.87. 276,180 shares of the stock were exchanged, compared to its average volume of 806,083. The company has a current ratio of 8.66, a quick ratio of 7.83 and a debt-to-equity ratio of 0.95. The firm has a market cap of $2.04 billion, a P/E ratio of -82.53 and a beta of 1.68. Pacira Pharmaceuticals Inc has a 1 year low of $26.95 and a 1 year high of $55.00.

Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its earnings results on Thursday, November 1st. The company reported $0.31 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.40. The company had revenue of $83.45 million during the quarter, compared to analyst estimates of $79.87 million. Pacira Pharmaceuticals had a negative net margin of 1.30% and a positive return on equity of 2.74%. Pacira Pharmaceuticals’s revenue for the quarter was up 23.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.11 earnings per share. Research analysts forecast that Pacira Pharmaceuticals Inc will post -0.02 earnings per share for the current fiscal year.

A number of research analysts have recently issued reports on PCRX shares. Needham & Company LLC set a $60.00 price objective on Pacira Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, November 1st. ValuEngine cut Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, October 2nd. Piper Jaffray Companies set a $55.00 price objective on Pacira Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, November 1st. Canaccord Genuity set a $45.00 price objective on Pacira Pharmaceuticals and gave the company a “hold” rating in a research note on Tuesday, September 4th. Finally, JPMorgan Chase & Co. raised their price objective on Pacira Pharmaceuticals from $45.00 to $50.00 and gave the company a “neutral” rating in a research note on Friday, November 2nd. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and ten have issued a buy rating to the company. Pacira Pharmaceuticals has an average rating of “Hold” and an average price target of $52.28.

Institutional investors have recently bought and sold shares of the company. Bouchey Financial Group Ltd purchased a new stake in shares of Pacira Pharmaceuticals during the third quarter worth about $221,000. Boston Private Wealth LLC purchased a new stake in shares of Pacira Pharmaceuticals during the third quarter worth about $246,000. First Republic Investment Management Inc. purchased a new stake in shares of Pacira Pharmaceuticals during the third quarter worth about $258,000. Parametrica Management Ltd purchased a new stake in shares of Pacira Pharmaceuticals during the third quarter worth about $259,000. Finally, Baird Financial Group Inc. purchased a new stake in shares of Pacira Pharmaceuticals during the third quarter worth about $288,000.

COPYRIGHT VIOLATION NOTICE: “Pacira Pharmaceuticals Inc (PCRX) Director Sells $2,976,901.95 in Stock” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2018/11/13/pacira-pharmaceuticals-inc-pcrx-director-sells-2976901-95-in-stock.html.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.

Featured Story: Tariff

Insider Buying and Selling by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.